Early research (Phase 1)Study completedNCT03523819What this trial is testingCS1002 in Subjects with Advanced Solid TumorsWho this might be right forSolid Tumor, Adult CStone Pharmaceuticals 91
Large-scale testing (Phase 3)Looking for participantsNCT06246916What this trial is testingA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Who this might be right forMelanoma Regeneron Pharmaceuticals 560
Very early researchLooking for participantsNCT07598578What this trial is testingAn Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.Who this might be right forPeripheral T-Cell Lymphoma Refractory Second Affiliated Hospital of Soochow University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04379739What this trial is testingNeoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung CancerWho this might be right forNon Small Cell Lung Cancer Shanghai Pulmonary Hospital, Shanghai, China 89
Not applicableLooking for participantsNCT05707819What this trial is testingSintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal CarcinomaWho this might be right forNasopharyngeal CarcinomaSintilimab Cancer Hospital of Guangxi Medical University 43
Early research (Phase 1)Active Not RecruitingNCT04042701What this trial is testingDS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerWho this might be right forBreast CancerNon-small Cell Lung Carcinoma Daiichi Sankyo 115
Testing effectiveness (Phase 2)Ended earlyNCT01420965What this trial is testingSipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate CancerWho this might be right forProstatic Neoplasms Augusta University 7
Not applicableUnknownNCT02938728What this trial is testingDefinition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced MelanomaWho this might be right forMalignant Melanoma Assistance Publique - Hôpitaux de Paris 120
Testing effectiveness (Phase 2)UnknownNCT05216237What this trial is testingEvaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) CancerWho this might be right forGastric CancerChemotherapyImmunotherapy Jiuda Zhao 31
Testing effectiveness (Phase 2)WithdrawnNCT03554395What this trial is testingStudy of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric CancerWho this might be right forAdvanced Gastric Cancer Fuda Cancer Hospital, Guangzhou
Large-scale testing (Phase 3)Active Not RecruitingNCT04165317What this trial is testingSasanlimab in People With Non-muscle Invasive Bladder CancerWho this might be right forNon-muscle Invasive Bladder Cancer Pfizer 1,068
Testing effectiveness (Phase 2)Ended earlyNCT03476174What this trial is testingAnti-PD-1 Antibody With HD IL-2 in Metastatic MelanomaWho this might be right forMelanoma Ralph Hauke 1
Large-scale testing (Phase 3)UnknownNCT03427827What this trial is testingPD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaWho this might be right forNasopharyngeal Neoplasms Sun Yat-sen University 450
Early research (Phase 1)UnknownNCT03251313What this trial is testingPD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) PatientsWho this might be right forTriple Negative Breast Cancer Fudan University 31
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07837362What this trial is testingSCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal CancerWho this might be right forEarly Low Rectal Cancer Fudan University 34
Not applicableUnknownNCT04322591What this trial is testingChemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON TrialWho this might be right forNon-small Cell Lung Cancer Hunan Province Tumor Hospital 70
Early research (Phase 1)WithdrawnNCT01386502What this trial is testingCT-011 and p53 Genetic Vaccine for Advanced Solid TumorsWho this might be right forBreast CancerColon CancerPancreatic Cancer+2 more National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT05490719What this trial is testingA Phase II Study of CRT Combined With QL1706 in ESCC PatientsWho this might be right forEsophageal Squamous Cell Carcinoma Tianjin Medical University Cancer Institute and Hospital 39
Testing effectiveness (Phase 2)Study completedNCT04732494What this trial is testingAnti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaWho this might be right forEsophageal Squamous Cell Carcinoma BeiGene 125
Early research (Phase 1)UnknownNCT03527251What this trial is testingAnti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLCWho this might be right forNon Small Cell Lung Cancer Sun Yat-sen University 10